222 related articles for article (PubMed ID: 23313168)
1. Anti-angiogenic activity of rPAI-1(23) and vasa vasorum regression.
Mulligan-Kehoe MJ
Trends Cardiovasc Med; 2013 May; 23(4):114-20. PubMed ID: 23313168
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice.
Mollmark JI; Park AJ; Kim J; Wang TZ; Katzenell S; Shipman SL; Zagorchev LG; Simons M; Mulligan-Kehoe MJ
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2644-51. PubMed ID: 22982464
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic activity of rPAI-1(23) promotes vasa vasorum regression in hypercholesterolemic mice through a plasmin-dependent mechanism.
Mollmark J; Ravi S; Sun B; Shipman S; Buitendijk M; Simons M; Mulligan-Kehoe MJ
Circ Res; 2011 Jun; 108(12):1419-28. PubMed ID: 21546607
[TBL] [Abstract][Full Text] [Related]
4. The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque.
Drinane M; Mollmark J; Zagorchev L; Moodie K; Sun B; Hall A; Shipman S; Morganelli P; Simons M; Mulligan-Kehoe MJ
Circ Res; 2009 Feb; 104(3):337-45. PubMed ID: 19122176
[TBL] [Abstract][Full Text] [Related]
5. Plaque-associated vasa vasorum in aged apolipoprotein E-deficient mice exhibit proatherogenic functional features in vivo.
Rademakers T; Douma K; Hackeng TM; Post MJ; Sluimer JC; Daemen MJ; Biessen EA; Heeneman S; van Zandvoort MA
Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):249-56. PubMed ID: 23241413
[TBL] [Abstract][Full Text] [Related]
6. The vasa vasorum in diseased and nondiseased arteries.
Mulligan-Kehoe MJ
Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H295-305. PubMed ID: 19940078
[TBL] [Abstract][Full Text] [Related]
7. Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease.
Sedding DG; Boyle EC; Demandt JAF; Sluimer JC; Dutzmann J; Haverich A; Bauersachs J
Front Immunol; 2018; 9():706. PubMed ID: 29719532
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis Inhibitor, Endostar, Prevents Vasa Vasorum Neovascularization in a Swine Atherosclerosis Model.
Xu X; Mao W; Chai Y; Dai J; Chen Q; Wang L; Zhuang Q; Pan Y; Chen M; Ni G; Huang Z
J Atheroscler Thromb; 2015; 22(10):1100-12. PubMed ID: 26016418
[TBL] [Abstract][Full Text] [Related]
9. Role of the vasa vasorum and vascular resident stem cells in atherosclerosis.
Kawabe J; Hasebe N
Biomed Res Int; 2014; 2014():701571. PubMed ID: 24724094
[TBL] [Abstract][Full Text] [Related]
10. Vasa vasorum and atherosclerosis - Quid novi?
Langheinrich AC; Kampschulte M; Buch T; Bohle RM
Thromb Haemost; 2007 Jun; 97(6):873-9. PubMed ID: 17549287
[TBL] [Abstract][Full Text] [Related]
11. Role of lipids and intraplaque hypoxia in the formation of neovascularization in atherosclerosis.
Chistiakov DA; Melnichenko AA; Myasoedova VA; Grechko AV; Orekhov AN
Ann Med; 2017 Dec; 49(8):661-677. PubMed ID: 28797175
[TBL] [Abstract][Full Text] [Related]
12. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.
Kaiser M; Younge B; Björnsson J; Goronzy JJ; Weyand CM
Am J Pathol; 1999 Sep; 155(3):765-74. PubMed ID: 10487834
[TBL] [Abstract][Full Text] [Related]
13. Targeting vasa vasorum dysfunction to prevent atherosclerosis.
Boyle EC; Sedding DG; Haverich A
Vascul Pharmacol; 2017 Sep; 96-98():5-10. PubMed ID: 28830735
[TBL] [Abstract][Full Text] [Related]
14. Tongxinluo mitigates atherogenesis by regulating angiogenic factors and inhibiting vasa vasorum neovascularization in apolipoprotein E-deficient mice.
Ma L; Ni M; Hao P; Lu H; Yang X; Xu X; Zhang C; Huang S; Zhao Y; Liu X; Zhang Y
Oncotarget; 2016 Mar; 7(13):16194-204. PubMed ID: 26908443
[TBL] [Abstract][Full Text] [Related]
15. Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Heriansyah T; Nafisatuzzamrudah N; Aini FN; Ridwan M; Primardhika RF; Wijayanti M; Bekti RS; Wihastuti TA
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):114-119. PubMed ID: 30394217
[TBL] [Abstract][Full Text] [Related]
16. Pericyte-specific deletion of ninjurin-1 induces fragile vasa vasorum formation and enhances intimal hyperplasia of injured vasculature.
Horiuchi K; Kano K; Minoshima A; Hayasaka T; Yamauchi A; Tatsukawa T; Matsuo R; Yoshida Y; Tomita Y; Kabara M; Nakagawa N; Takehara N; Hasebe N; Kawabe JI
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2438-H2447. PubMed ID: 33961504
[TBL] [Abstract][Full Text] [Related]
17. Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia.
Herrmann J; Best PJ; Ritman EL; Holmes DR; Lerman LO; Lerman A
J Am Coll Cardiol; 2002 May; 39(9):1555-61. PubMed ID: 11985922
[TBL] [Abstract][Full Text] [Related]
18. The dynamic vasa vasorum.
Ritman EL; Lerman A
Cardiovasc Res; 2007 Sep; 75(4):649-58. PubMed ID: 17631284
[TBL] [Abstract][Full Text] [Related]
19. Quantification of plaque neovascularization using contrast ultrasound: a histologic validation.
Moguillansky D; Leng X; Carson A; Lavery L; Schwartz A; Chen X; Villanueva FS
Eur Heart J; 2011 Mar; 32(5):646-53. PubMed ID: 20581005
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice.
Veerman KJ; Venegas-Pino DE; Shi Y; Khan MI; Gerstein HC; Werstuck GH
Atherosclerosis; 2013 Apr; 227(2):250-8. PubMed ID: 23411040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
